neurology
Movement disorders

S8 restrictions to remain on medical cannabis spray for MS spasticity

The TGA has rejected a bid to improve access to a medical cannabis spray for MS spasticity symptoms by down-scheduling it from Schedule 8 to Schedule 4 status. The nabiximols oromucosal spray (Sativex) is licensed by the TGA as a prescription (Schedule 8) medicine for the treatment of adults with spasticity due to multiple sclerosis, ...

Already a member?

Login to keep reading.


OR
© 2021 the limbic